At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open-Label, Randomized Phase II Trial to Evaluate Hematologic Toxicities After HIPEC With Oxaliplatin or Mitomycin C in Patients With Appendiceal Tumors
In Brief
A Phase 2 clinical trial evaluating mitomycin C, oxaliplatin, and 3 other interventions for Carcinoma of the Appendix and Primary Peritoneal Cavity Cancer. Completed, enrolled 136 participants across 3 sites.
Detailed Summary
This randomized phase II trial is studying the side effects and how well giving oxaliplatin or mitomycin C directly into the abdomen after surgery works in treating patients with tumors of the appendix. Drugs used in chemotherapy, such as oxaliplatin and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more tumor cells. Giving these treatments after surgery may kill any tumor cells that remain after surgery.
Study Details
Timeline
Interventions
Given by HIPEC
Given by HIPEC
Undergo surgery
Ancillary studies
Undergo HIPEC